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Adeno-associated virus type 9 (AAV9) is a powerful tool 
for  delivering  genes  throughout  the  central  nervous 
system (CNS) following intravenous injection. Preclini-
cal results in pediatric models of spinal muscular atro-
phy (SMA) and lysosomal storage disorders provide a 
compelling case for advancing AAV9 to the clinic. An 
important translational step is to demonstrate efficient 
CNS targeting in large animals at various ages. In the 
present study, we tested systemically injected AAV9 in 
cynomolgus macaques, administered at birth through 3 
years of age for targeting CNS and peripheral tissues. We 
show that AAV9 was efficient at crossing the blood–brain 
barrier (BBB) at all time points investigated. Transgene 
expression was detected primarily in glial cells through-
out the brain, dorsal root ganglia neurons and motor 
neurons within the spinal cord, providing confidence for 
translation to SMA patients. Systemic injection also effi-
ciently targeted skeletal muscle and peripheral organs. 
To specifically target the CNS, we explored AAV9 deliv-
ery to cerebrospinal fluid (CSF). CSF injection efficiently 
targeted motor neurons, and restricted gene expression 
to the CNS, providing an alternate delivery route and 
potentially lower manufacturing requirements for older, 
larger patients. Our findings support the use of AAV9 
for gene transfer to the CNS for disorders in pediatric 
populations.
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2 August 2011. doi:10.1038/mt.2011.157
IntroductIon
The recent discovery that adeno-associated virus type 9 (AAV9) 
can cross the blood–brain barrier (BBB) and produce extensive 
transgene  expression  in  the  brain  and  spinal  cord  suggests  a 
powerful, noninvasive method to deliver genes to the central ner-
vous system (CNS). Preclinical results in models of pediatric neu-
rological diseases with widespread pathology indicate systemic 
gene delivery could have profound therapeutic benefits, such as 
in spinal muscular atrophy (SMA). SMA is the most common 
autosomal recessive disease of early childhood with an incidence 
of 1:6–10,000 live births. In its most common and severe form 
(type 1), hypotonia and progressive weakness are recognized in 
the first few months of life, leading to diagnosis by 6 months of 
age and death due to respiratory failure by age two.1 There is no 
treatment available to slow or halt disease progression, but recent 
preclinical  studies  utilizing  gene  delivery  in  newborn  rodent 
models of SMA suggest gene therapy may hold promise.2–4 SMA 
is an attractive disease for gene therapy because it is a single gene 
defect that most frequently results in low amounts of the survival 
motor neuron (SMN) protein versus a total deficiency.1 SMN is a 
ubiquitously expressed protein that is essential in all tissues and is 
not associated with toxicity when over expressed.2–8 In addition, 
disease  severity  correlates  with  SMN  protein  levels  suggesting 
that increasing SMN may be beneficial for patients.6 Motor neu-
rons are the cell type primarily responsible for pathology of SMA, 
which has precluded the development of an SMA gene therapy 
due to inefficient targeting of these cells by recombinant vectors.9 
However,  the  recent  discovery  that  AAV9  can  target  ~60%  of 
motor neurons after systemic injection makes efficient delivery to 
the CNS feasible.10,11
A critical step in the translation of an SMA therapy to clinic 
is the demonstration of CNS targeting in nonhuman primates. 
AAV9’s crossing of the BBB has been demonstrated in mice, rats, 
and cats indicating promise for translation to a human popula-
tion.10–13  Importantly,  we  demonstrated  that  AAV9  can  target 
motor  neurons  following  intravenous  injection  in  a  1-day-old 
cynomolgus  macaque.3  However,  the  data  in  mice  suggests  a 
window  of  opportunity  for  targeting  motor  neurons  in  young 
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primates may remain as a potential clinical obstacle for advancing 
AAV9 gene delivery for SMA. When AAV9 is systemically admin-
istered to newborn mice, there is extensive neuronal transduction 
throughout the brain and spinal cord. However, when adminis-
tered to adult mice, the majority of transduced cells are positive 
for astrocytic markers.11 Our studies in mice demonstrated that 
this “switch” in targeted cell types occurred within the first 10 days 
of life as demonstrated by a progressive decline in motor neuron 
transduction between P2 and P10.3
For this reason, we examined transgene expression through-
out the body of male cynomolgus macaques following vascular 
delivery at time points from birth through 3 years of age using 
self-complementary AAV9 delivery of green fluorescent protein 
(GFP)  versus  phosphate-buffered  saline  (PBS)  controls.  In  the 
present work, we expand our earlier findings that systemically 
administered AAV9 can efficiently target motor neurons in a new-
born nonhuman primate with the addition of successful motor 
neuron targeting in animals up to 3 years of age. We also demon-
strate extensive transduction of primarily glial cells throughout 
the brains of all treated animals. We extend our examination to 
tissues outside of the CNS and report extensive transgene expres-
sion within skeletal muscle and multiple organs. Because system-
wide transduction may not be desirable in every paradigm, we 
investigated intrathecal and intracisternal delivery of AAV9 in 
newborn pigs for its ability to produce CNS transduction.14 We 
demonstrate that motor neurons and regions of the brain can be 
targeted in neonatal pigs using AAV9 delivery to cerebrospinal 
fluid (CSF), potentially increasing the specificity and lowering the 
viral dose required for efficacy.15 Together these findings are sup-
portive of advancing AAV9-based gene delivery to the clinic for 
treatment of newly diagnosed type 1 SMA patients. In addition 
to SMA, the extensive transduction seen in the brain at all time 
points suggests applications for other pediatric neurological dis-
eases with global pathology such as Rett syndrome and lysosomal 
storage disorders.
results
systemic injection of AAV9 targets motor neurons  
in nonhuman primates through 3 months
The observation that, in mice, the cell types targeted by systemic 
injection of AAV9 shifted from neurons to astrocytes early in 
postnatal life could impact the potential clinical utility of AAV9. 
To address whether this pattern was unique to rodents, we sought 
to define a window of opportunity for targeting motor neurons 
in nonhuman primates following systemic delivery of AAV9-GFP. 
We performed systemic injections of 1–3 × 1014 vg/kg in a maxi-
mum volume of 10 ml of self-complementary AAV9-GFP with a 
chicken β-actin hybrid promoter, a cytomegalovirus immediate 
early enhancer and an SV40 intron. This is the same promoter 
construct previously used in our initial AAV9 report as well as in 
our rescue of the SMA mouse model report.3,11 With the exception 
of P1 animals, serum samples from male cynomolgus macaques 
were screened for the presence of binding antibodies against AAV9 
capsids using an anti-AAV9 enzyme-linked immunosorbent assay. 
Animals that were seronegative at 1:50 (the lowest dilution tested) 
for anti-AAV9 antibodies were injected through the saphenous 
vein at postnatal day 1, 30, or 90 (P1, P30, or P90, respectively). 
Animals  were  killed  21–25  days  postinjection  and  tissues  col-
lected for analysis. We performed in situ hybridization on lumbar 
spinal cord sections of the AAV9 GFP- and PBS-injected mon-
keys. Use of an antisense probe against the GFP mRNA detected 
abundant signal (Figure 1a,c,e; dark blue dots) that colocalized 
with a nuclear counter stain (pink) in the vector-treated animals. 
GFP expression was seen in large neurons of the ventral horn and 
within small nuclei throughout the gray and white matter of all 
the AAV-treated monkeys. Nearly all of the large neuronal-like 
cells displayed detectable levels of positive signal with additional 
cells targeted throughout the spinal cord, which likely demon-
strates non-neuronal transduction. PBS-treated animals had no 
detectable signal in any of the sections examined (Figure 1g). To 
confirm that the signal was not the result of nonspecific binding 
of the antisense probe, tissue sections from the same animals were 
exposed to a sense probe which does not bind mRNA. Importantly, 
there was no hybridization in sections from either vector or PBS-
treated animals when using the sense probe (Figure 1b,d,f,h).
To identify the GFP+ neurons in the spinal cord, we immuno-
labeled tissue sections for transgene and choline acetyl transferase 
(ChAT), a motor neuron marker. Examination of labeled sections 
at all levels of the spinal cord demonstrated extensive GFP labeling 






Figure 1  In situ hybridization of monkey spinal cords following intra-
venous  injection  of  either  adeno-associated  virus  type  9  (AAV9)-
green fluorescent protein (GFP) or phosphate-buffered saline (PBs). 
Regions of lumbar spinal cords were probed with either antisense (a,c,e, 
and g) or sense (b,d,f, and h) probes against the vector-derived GFP 
mRNA then counterstained with fast-red as a nuclear label. Within sec-
tions incubated with antisense probe, positive labeling is shown in dark 
blue, and is detected in large ventral neurons (filled arrows) and glia 
(open arrows) throughout both the gray and white matter of all animals 
injected with AAV9-GFP. There was no detectable signal when vector-
treated tissues were incubated with the sense probe indicating a lack of 
nonspecific probe binding. PBS-treated animals had no detectable signal 
with either the antisense or sense probes.Molecular Therapy  vol. 19 no. 11 nov. 2011  1973
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GFP+ nerve fibers were also detected coursing through the dor-
somedial white matter indicative of transgene expression within 
the ganglion cells of the dorsal root (Supplementary Figure S1). 
As seen with mice, GFP expression within neurons in the paren-
chyma of the spinal cord was confined to ChAT+ cells. There was 
also GFP+ cells with glial morphology that were sparsely scattered 
throughout the sections examined (data not shown). The overall 
pattern as detected by GFP immunohistochemistry was similar to 
that seen after neonatal delivery of AAV9 in rodents and cats with 
expression primarily in neuronal cells that project into the periph-
ery.10,11 Importantly, efficient motor neuron targeting with AAV9 
persists through at least the first three postnatal months.
Intravascular delivery of AAV9 targets motor neurons 
in a 3-year-old cynomolgus macaque
Due to successful targeting of motor neurons through the first 3 
months of life in nonhuman primates, we asked whether motor 
neurons  could  still  be  targeted  in  a  3-year-old  cynomolgus 
macaque. Utilizing interventional radiological techniques, a cath-
eter was threaded through the brachial artery to the descending 
aorta while a balloon catheter was simultaneously fed through 
the femoral artery to the celiac artery and transiently inflated 
during vector injection. A dose of 2.7 × 1013 vg/kg of AAV9-GFP 
was administered to the descending aorta while partially occlud-
ing blood flow to the liver in a procedure designed to give “first-
pass” of the virus through the spinal arteries that are responsible 
for blood flow to the nerve roots of the thoracic cord. Two weeks 
postinjection;  the  animal  was  killed  and  examined  for  GFP 
expression using in situ hybridization and GFP immunofluores-
cence. As with the P1–P90 animals, antisense probed sections of 
spinal cord indicated GFP expression within both neuronal and 
glial cells of the spinal cord, while sense probed sections showed 
no signal (Supplementary Figure S2a,b). GFP and ChAT immu-
nofluorescent  examination  of  cervical,  thoracic,  and  lumbar 
spinal cord sections revealed GFP+ motor neurons at all levels 
though less frequently than in younger animals (Supplementary 
Figure S2c,e). The apparent decrease in motor neuron transduc-
tion may be due to 1/10 the dose given to the 3-year-old animal 
compared to that of the P1–P90 group. Nevertheless, this is the 
proof that motor neurons can still be targeted utilizing systemic 
AAV9 delivery in a juvenile cynomolgus macaque even at signifi-
cantly lower doses.
Intravascular AAV9 produces extensive glial 
transduction throughout the brain
We next examined brain transduction following systemic deliv-
ery of AAV9. Indeed in mice, intravenous injection of AAV9 
produced  high  levels  of  neuronal  transduction  in  the  brain, 
therefore, we examined the brains of the treated monkeys for 
GFP expression utilizing immunohistochemistry.11 As performed 
with the spinal cords, whole mount brains were sectioned in a 
serial manner and evaluated for GFP expression. Representative 
sections  using  high  resolution  slide  scanning  are  shown  in 
Figure  3  (P1–P90)  and  Supplementary  Figure  S3  (3  years). 
Slide scanning technology captures images of the entire micro-
scope slide with up to ×40 resolution.16 All GFP-injected animals 
had extensive transgene expression throughout the entire brain. 
The overall pattern of expression was again similar to that seen 
in mice with the most abundant number of GFP-expressing cells 
in all cortical regions (Figure 3a,b,f–j,k,o), lateral geniculate 
(Figure 3a,d), midbrain, pons and medulla. Subcortical struc-
tures such as thalamus (Figure 3a,c) and putamen (Figure 3k,l) 
were also GFP+ but at a lower cell density. In contrast to the 
mice, primate brains of all ages had primarily glial transduc-
tion with microglia and astrocytes being the most prominent 
cell types targeted (Supplementary Figure S4) as determined 
by  colabeling  with  Iba-1  and  GFAP  (microglia  and  astrocyte 
marker,  respectively)  with  neurons  interspersed  throughout. 
The scarcity of neuronal transduction was most striking in the 
hippocampus (Figure 3k,n) and dentate gyrus of the nonhu-
man primates because, in mice, neurons of these regions were 
highly transduced in both neonate- and adult-treated animals.11 
Transduction was not restricted to gray matter (Figure 3k,m) 
and  included  scattered  oligodendrocytes  (data  not  shown). 
Surprisingly, widespread GFP expression was seen throughout 
the brain of the 3-year-old animal that received 1/10 the dose 
compared to the P1–P90 animals. The brain regions transduced 






Figure 2  Immunofluorescent labeling of green fluorescent protein 
(GFP) and choline acetyl transferase (chAt) within motor neurons. 
Lumbar spinal cord sections from adeno-associated virus type 9 (AAV9) 
or phosphate-buffered saline (PBS)-injected animals were labeled with 
antibodies against the vector-derived transgene (GFP; a,d,g, and j) and 
a motor neuron marker (ChAT; b,e,h, and k) and are shown in black 
and white for enhanced contrast. Merged images (c,f,i, and l), GFP in 
green and ChAT in red, indicate extensive transgene expression within 
motor neurons of the P1, P30, and P90-injected animals. GFP expres-
sion was not detected within the spinal cords of PBS-injected animals. 
All Bars = 200 µm.1974  www.moleculartherapy.org  vol. 19 no. 11 nov. 2011     
© The American Society of Gene & Cell Therapy
AAV9 Efficiently Targets the CNS in Large Animals
with cortical and pontine regions having the highest prevalence 
of transduced cells. GFP+ cells were predominantly astrocytes 
and microglia (data not shown) though neurons of cranial nerve 
nuclei also expressed GFP (Supplementary Figure S3b).
AAV9 transduces skeletal muscle  
and peripheral organs
Numerous groups have demonstrated the ability of AAV to effi-
ciently  target  skeletal  muscle  in  mice,  dogs,  and  primates.17–21 
Therefore,  we  examined  skeletal  muscle  of  the  AAV9-injected 
nonhuman primates for GFP expression. In the young monkeys 
(P1–P90), all skeletal muscles examined were positive for GFP 
using immunofluorescent detection (Figure 4) including triceps, 
diaphragm,  transverse  abdominus,  quadriceps,  gastrocnemius, 
tibialis anterior, and tongue. Skeletal muscles sampled were from 
the brachial and pelvic limbs, head, and trunk indicating a body-
wide distribution. GFP expression was less abundant in the skeletal 
muscles of the lower dosed, older monkey though still detectable 
in most muscles (data not shown).
Peripheral organs may also be a target of a systemically injected 
vector, therefore, we collected organs from injected animals to 
look  for  GFP  expression  within  tissues  (Figure  5).  Although, 
P1 P30
P90 CTL
Figure 3  Whole slide scans of adeno-associated virus type 9 (AAV9) 
and  phosphate-buffered  saline  (PBs)-injected  monkey  brains. 
Representative sections through similar regions of brains from systemi-
cally injected monkey were immunolabeled with anti-GFP antibodies. 
Panels a,f, and k show uniform labeling throughout the sections of 
AAV9-injected animals but not the (p) PBS-injected animals. Boxes and 
arrows indicate the approximate regions from where the high magni-
fication images were acquired. Cortex (a,b,f–j,k, and o) consistently 
had the highest density of GFP-expressing cells at all time points as did 
the lateral geniculate (a,d). Subcortical structures such as thalamus (a,c) 
and putamen (l,k) were well transduced but at a lower density than 
cortex. GFP+ cells were also seen within white matter of the pons (a,f,e) 
and cortex (k,m), as well as within the hippocampus (k,n). The majority 
of GFP+ cells in all regions had glial morphology though individual neu-
rons could be detected throughout the brain. Brains from PBS-injected 












P1 P30 P90 PBS
Figure 4  Green fluorescent protein (GFP) expression within nonhu-
man primate skeletal muscle. GFP immunofluorescence from adeno-
associated virus type 9 (AAV9)-injected and phosphate-buffered saline 
(PBS)-injected  monkeys  demonstrates  extensive  transgene  expression 
in  skeletal  muscles  of  all  AAV9-injected  animals.  GFP  expression  was 
detected in the brachial limbs (triceps brachii a–c), trunk [diaphragm e–g 
and transverse abdominus (TVA) i–k], pelvic limbs (quadriceps m–o, 
gastrocnemius q–s, and tibialis anterior u–w) and head (tongue x–z) of 
AAV9 systemically injected animals. No GFP signal was detected in any of 
the muscle from the PBS-injected animals (d,h,l,p,t, and aa).Molecular Therapy  vol. 19 no. 11 nov. 2011  1975
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we could detect native GFP expression, we utilized an antibody 
against GFP to enhance detection levels. As expected, liver had the 
highest levels of GFP expression, followed by the adrenal medulla 
(P1-injected  animal).  Previous  studies  demonstrated  that  the 
heart, while well targeted in mice by AAV9, is not as efficiently 
transduced in dogs.18,22 Our findings in the AAV9-treated mon-
keys agree with those in dog, in that levels of GFP expression in 
the heart were lower relative to skeletal muscle. GFP signal was 
also found in the germinal centers of the spleen in all of the treated 
animals as well as smooth muscle that lines the intestines. GFP 
expression was also detected in the Leydig cells of the testes of 
all treated male monkeys. Finally, occasional positive cells were 
identified in the lungs and kidneys of AAV9 GFP-treated animals. 
These results demonstrate that systemic gene delivery targets mul-
tiple organ systems with a biodistribution of expression similar to 
that found in the rodent with the exception of cardiac tissue.
AAV9 injection into cerebral spinal fluid  
of young pigs efficiently targets motor neurons
Although some neurological disorders are caused by defects in 
ubiquitously expressed proteins, in other disorders gene expres-
sion in the CNS alone may have a substantial impact.23–25 Gene 
delivery to the CSF could produce transduction along the neuraxis 
with the added benefit of potentially lowering the required dose. 
In order to examine more localized CNS delivery we performed 
intrathecal and/or intracisternal injections of 5.2 × 1012 vg/kg of 
AAV9 GFP into 5-day-old pigs (n = 3 each) and examined their 
brains and spinal cords for GFP expression. In all animals, GFP 
expression was seen in the dorsal root ganglia as well as the spi-
nal cord gray and white matter. Importantly, AAV9 GFP injec-
tion into either the cisternal space at the base of the skull or the 
intrathecal space at L5 resulted in extensive motor neuron trans-
duction at all levels of the spinal cord (Figure 6a–d) as examined 
by in situ hybridization. Large ventral horn neurons were also 
positive for GFP expression by immunohistochemistry at all lev-
els of spinal cord (Figure 6e–l). Immunofluorescence confirmed 
that the GFP+ cells expressed the motor neuron marker ChAT 
(Figure 6m–r).
AAV9 injection into the csF produces transgene 
expression in the brain
Finally, to further characterize the pattern of expression follow-
ing cisternal or intrathecal injection of AAV9-GFP into 5-day-old 
pigs, we examined brains for transgene expression again using 
GFP immunofluorescence (Figure 7). The regions with the high-
est levels of GFP expression were cerebellar Purkinje cells, nerve 
fibers within the medulla as well as discrete nuclei, such as the oli-
vary nucleus. Expression within the rest of the brain was restricted 
to scattered cells near the meningeal surfaces (data not shown). 
Examination of GFP expression in peripheral organs yielded no 
visible GFP expression indicating that the majority of the virus 
was localized to the CNS.
dIscussIon
The recent emergence of AAV9 and its ability to cross the BBB 
represents  a  potentially  valuable  therapeutic  and  basic  science 
tool. The consistency of performance across species only adds to 
AAV9’s value. Our previous work and the data presented here are 
among the first to demonstrate transgene expression within the 
entire CNS following a peripheral systemic injection in nonhu-
man primates.3,12 That a similar pattern of expression is generated 
in animals of multiple ages is excellent proof-of-concept that this 
delivery modality can be advanced to the clinic, especially for 
pediatric diseases with broad targeting needs.
A recent study also looked at systemic injection of AAV9 for 
its ability to cross the BBB in nonhuman primates.12 Both the pres-
ent and previous studies report transgene expression along the 
entire neuraxis of nonhuman primates. What is further encourag-
ing about the two data sets is that Gray et al. worked exclusively 


















P1 P30 P90 PBS
Figure 5  Green fluorescent protein (GFP) expression within assorted 
organs. Of the tissues examined, GFP expression was most abundant 
in the (a–c) livers and (u) adrenal medulla of all AAV9-injected mon-
keys. Detectable GFP expression was also seen in the (e–g) kidney, (i–k) 
spleen, (m–o) heart, (q–s) lung, (v–x) smooth muscle of the intestines, 
and(z–bb) testes of AAV-injected animals. GFP was not detected in the 
tissues collected from PBS-injected animals (d,h,l,p,t, and y).1976  www.moleculartherapy.org  vol. 19 no. 11 nov. 2011     
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versus ~1 × 1014 vg/kg) the dose used in the present study for the 
P1–P90 animals and comparable to our 3-year-old animal (2.7 × 
1013 vg/kg). The overlap in the 3-year-old age group between the 
two studies calls into question whether the interventional radiolog-
ical techniques employed in the present study conferred an advan-
tage with respect to first-pass CNS transduction. The occlusion of 
blood flow to the liver may be beneficial in improving transduc-
tion to other tissues, however, further studies are needed to assess 
the efficacy of procedurally detargeting the liver. Furthermore, 
emerging  techniques  in  capsid  evolution  for  enhancements  of 
vectors have also shown effectiveness in detargeting the liver26 and 
requires additional study for systemic gene delivery to the brain. 
Nonetheless, together the data suggest that CNS targeting follow-
ing systemic injection of AAV9 is feasible in animals from birth 
through 4 years of age over a range of doses. A noteworthy find-
ing between the two studies is the consistent targeting of motor 
neurons in all of the animals examined regardless of age. These 
findings will certainly have impact on the development of gene 
delivery protocols for SMA. Whereas type 1 SMA patients are 
the most severe and most common, a significant patient popu-
lation exists with type 2 and type 3 disease that manifests later 
in life and produces milder though still debilitating symptoms.27 
The field’s knowledge of the molecular pathology of mild SMA is 
hampered by the fact that lifespan is often not affected in these 
patients and a robust animal model is not available for study.28 The 
preclinical SMN gene delivery studies were performed in a mouse 
model that closely resembles type 1 patients and therefore sup-
ports a trial within those patients.2–4 However, because gene deliv-
ery to motor neurons can be accomplished at later time points in 
higher species, it gives hope for later trials in less severe patients. 
An important question remains though, as to whether type 2 and 
type 3 patients would benefit from SMN gene restoration within 
motor neurons at their stage of disease. Outside of motor neurons, 
the fact that lower doses in larger animals produced appreciable 
Figure 6  Pig spinal cord after adeno-associated virus type 9 (AAV9) injection. In situ hybridization of AAV9 (a–b) or phosphate-buffered saline 
(PBS) (c–d)-injected spinal cords reveals green fluorescent protein (GFP) signal within motor neurons (filled arrows) and glia (open arrows) of 
antisense probed sections of (a) AAV-injected pigs but not (c) PBS injected. Sense probed sections from both treated and control animals had no 
detectable signal (b and d). Immunohistochemical detection of GFP following (e–h) intracisternal or (i–l) intrathecal-injected spinal cords indicates 
extensive labeling of large ventral horn neurons within AAV9-injected (e–g and i–k) but not PBS-injected animals (h and l). Immunofluorescent cola-
beling of GFP (n and q) and ChAT (o and r) in spinal cord sections from intracisternal or intrathecal AAV9-injected pigs shows that the transduced 
cells are motor neurons (merged, m and p). C.sc, cervical spinal cord, T.sc, thoracic spinal cord; L.sc, lumbar spinal cord.Molecular Therapy  vol. 19 no. 11 nov. 2011  1977
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transgene expression within the CNS supports the development of 
therapies for diseases with secreted transgenes such as lysosomal 
storage disorders.29
The studies by Gray et al. in 3–4-year-old Nonhuman primates 
show that poor expression was seen in the presence of pre-existing 
antibodies following systemic delivery.12 In human clinical trials, 
transgene expression can be achieved following direct injection 
into muscle or brain despite pre-existing neutralizing antibod-
ies.30,31 While more information is needed regarding the prevalence 
of neutralizing antibodies to AAV9 within the adult population, 
the epidemiological data suggests that the overwhelming majority 
of the adult population is seronegative for neutralizing antibodies 
against newer AAV serotypes.32–34 For example, AAV2 is the sero-
type with the highest prevalence of neutralizing antibodies rang-
ing from 20 to 60% of the population at a 1:20 dilution, and the 
prevalence of individuals with neutralizing antibodies to emerg-
ing serotypes such as AAV8 was among the lowest tested (19–32% 
at a 1:20 dilution) across multiple continents.33 Of interest, in a 
French adult population <50% of individuals from 25 to 64 years 
old were seropositive for AAV9-binding antibodies, of which only 
~33% inhibited in vitro infection. Among those seropositive for 
anti-AAV9 antibodies, ~70% had very low antibody titers of 1:20 
which was the lowest dilution tested.32 Studies in children report 
that the prevalence of anti-AAV antibodies in children is less than 
that of adults, indicating the age of acquisition of infection may 
also factor favorably into delivery into a pediatric population.35,36 
It is also possible to transiently reduce or eliminate neutralizing 
antibodies via apheresis which may allow gene targeting even in 
seropositive patients.37
An important goal of this study was to address the existence 
of a window of opportunity for motor neuron targeting in non-
human primates. In mice, systemic injection of AAV9 into older 
animals (P10 and older) led to a dramatic increase in the number 
of glia targeted within the spinal gray matter when compared to 
P1-injected mice.11 Concomitant with the increase in glial target-
ing was a decrease in motor neuron targeting which could compli-
cate patient selection in a clinical trial for SMA.3,11 The successful 
transduction of motor neurons in all the treated monkeys sug-
gests that the hypothetical window closes much later, if at all, in 
nonhuman primates. The data from both the spinal cord in situ 
hybridization and the monkey brain histology demonstrate glial 
cells are well transduced by AAV9 at all ages studied, suggesting 
that astrocytes may still be a viable target for AAV9 delivery under 
appropriate circumstances.
Another departure from the data generated in mice is the types 
of cells targeted in the brains of monkeys after systemic AAV9 
injection. Experiments in mice targeted predominantly neurons 
throughout the brains of neonate-injected animals, whereas in 
monkeys the cells targeted were mostly astrocytes and microglia. 
This discrepancy is likely due to the different timing of gliogen-
esis between the two species.38 Therefore, vector escaping from 
the vasculature in the primate brain would likely encounter glial 
endfeet that ensheathe the endothelial cells before meeting neu-
rons. Nonetheless, the number of neurological diseases that have 
implicated glial cells as contributing to pathology continues to 
grow.39 The abundance and distribution of cells targeted through-
out the primate brains of all the treated animals suggests AAV9 
gene delivery could have immense impact on diseases through-
out the nervous system, such as amyotrophic lateral sclerosis, Rett 
syndrome, and lysosomal storage diseases.29,40,41
The high amount of GFP expression throughout all the skel-
etal muscles examined is consistent with data from numerous 
groups in mice and dogs.18,22 Head-to-head comparisons would be 
required in nonhuman primates to determine whether the hier-
archy of muscle transducing serotypes from mice is consistent in 
monkeys. Transduction of peripheral organs is an expected side 
effect of systemic delivery. Indeed, the persistence of expression 
in the liver of the younger primates is noteworthy when compared 
to data in mice in which episomal viral genomes are lost through 
the rapid cell divisions of the developing mouse liver. However, 
the slower development of primates compared to rodents likely 
explains why we saw GFP persistence in the liver at the time of 
sacrifice; 3 weeks postinjection. For example, in the P1 animal 
there was a difference of only 4 g between birth and sacrifice 3 
weeks later. Similar vector doses in P1 mice also show the clear-
ance of transgene expression from liver as a factor of time post 
injection (data not shown). Therefore, we predict the expression 
of  transgene  in  nonhuman  primate  liver  would  diminish  over 
time, due to hepatocyte division. Depending on the paradigm, 
transduction of organs can be potentially beneficial or harmful, 
and techniques exist to restrict the viral expression to target cells 
such as motor neurons if needed.42–45 As for the tissues targeted 
in this study, our data is in agreement with data generated in cats 
Figure  7  Adeno-associated  virus  type  9  (AAV9)-green  fluorescent 
protein  (GFP)  mediates  transgene  expression  in  the  brain  after 
intrathecal delivery. Representative coronal brain section (a) showing 
GFP expression after intrathecal injection of AAV9-GFP within the hind-
brain, fibers of the trigeminal nerve (b) and Purkinje cells (c). (d–f) GFP 
expression was also detected in ChAT+ neuron of the olivary nucleus. Cb, 
cerebellum; NCH, nuclei cochleares; NSV, nucleus tractus spinalis nervi 
trigemini; TSV, tractus spinalis nervi trigemini.1978  www.moleculartherapy.org  vol. 19 no. 11 nov. 2011     
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that showed skeletal muscle, liver and adrenal medulla as highly 
transduced sites following systemic injection of AAV9.10
Anticipating  the  potential  requirement  to  avoid  off-target 
expression  of  corrective  transgenes  outside  the  CNS,  we  have 
also demonstrated that AAV9 delivery into the CSF can deliver 
transgene throughout the CNS with limited peripheral expres-
sion. Recent studies utilizing gene transfer for SMA into the lat-
eral ventricles and lumbar spinal cord of neonatal SMA mice had 
a profound effect on survival, though it is not clear how favorably 
it compares with systemic administration.24,25 Development of an 
intrathecal delivery paradigm would reduce viral load that in turn 
could reduce the risk of an immune response as well as decrease 
viral  production  requirements  particularly  for  older,  presum-
ably larger patients. Another complicating factor, at least in the 
context of SMA, is the involvement of non-neuronal tissues. Our 
group and others recently reported cardiac deficits in multiple 
SMA mouse models that could suggest the need for SMN pro-
tein in cells besides motor neurons.46–48 The relevance of similar 
heart findings in humans also remains to be elucidated. Designing 
studies to examine the contribution of cell types other than motor 
neurons to SMA pathology is difficult due to the models available 
due in part to early pathology and the small size of SMA mice.
The data presented here give increasing confidence that sys-
temic and intrathecal delivery of AAV9 will likely be successful 
when applied to pediatric neurological disease, potentially even in 
older children. The published preclinical efficacy data in a model of 
SMA and the effectiveness of motor neuron targeting within large 
animals in the current report highlight the need for safety studies 
utilizing SMN as the next step in advancing SMA gene delivery to 
clinical trial. The demonstration of motor neuron and glial target-
ing in large species opens the possibilities to the creation of large 
animal models of disease to address questions of subcellular local-
ization of proteins or the importance of aging to the manifesta-
tion of a disease phenotype. The repertoire of AAV9 and emerging 
serotypes are just beginning to be explored, yet is demonstrating 
significant potential in basic and translational science.49
MAterIAls And Methods
Viral  production.  Self-complementary  AAV9  was  produced  by  tran-
sient transfection procedures using a double-stranded AAV2-ITR-based 
CB-GFP vector, with a plasmid encoding Rep2Cap9 sequence as previously 
described along with an adenoviral helper plasmid pHelper (Stratagene, 
Santa Clara, CA) in 293 cells.50 Our serotype 9 sequence was verified by 
sequencing and was identical to that previously described. Virus was pro-
duced in three separate batches for the experiments and purified by two 
cesium chloride density gradient purification steps, dialyzed against PBS 
and formulated with 0.001% Pluronic-F68 to prevent virus aggregation 
and stored at 4 °C. All vector preparations were titered by quantitative-
PCR using Taq-Man technology. Purity of vectors was assessed by 4–12% 
sodium dodecyl sulfate-acrylamide gel electrophoresis and silver staining 
(Invitrogen, Carlsbad, CA).
Animal  care  and  use.  All  procedures  performed  were  in  accordance 
to  either  the  Mannheimer  Foundation  (Homestead,  FL),  the  Research 
Institute at Nationwide Children’s Hospital or The Ohio State University 
Institutional Animal Care and Use Committees.
Nonhuman primate intravascular vector delivery. The breeding, hous-
ing and procedures performed on the young, male cynomolgus macaques 
(Macaca fasciculata, age P1–P90) were carried out at the Mannheimer 
Foundation. Briefly, veterinary staff anesthetized the subject and placed a 
catheter into the saphenous vein, through which either a suspension of 1–3 
× 1014 vg/kg AAV9.CBA.GFP or PBS was infused over a period of 5–8 min-
utes. Upon recovery, subjects were returned to their mother and housed 
under routine conditions for the duration of the study.
At Nationwide Children’s Hospital, the 3-year-old subject was infused 
with 2.7 × 1013 vg/kg using interventional radiological techniques to target 
delivery to the radicular arteries of the thoracic cord. Briefly, the subject 
was anesthetized and a catheter was introduced percutaneously into the 
brachial artery and guided to the proximal portion of the descending 
aorta.  A  second  catheter  delivered  an  occlusive  balloon  to  the  distal 
portion of the descending aorta at the level of the celiac trunk. Proper 
placement was confirmed by fluoroscopy and injection of a radiopaque 
dye via the proximal catheter. Before injection, the distal balloon was 
inflated to occlude blood flow distal to and including the celiac trunk. The 
viral suspension was delivered over ~1 minute, and the balloon was left 
inflated for another 2 minutes postinfusion. After recovery, the animal was 
released back to its regular environment for the duration of the study.
Seronegativity for anti-AAV9 antibodies was confirmed in all subjects 
by enzyme-linked immunosorbent assay. Briefly, a 2 × 1010 vg/ml solution 
of empty AAV9 capsids was made with a carbonate coating buffer and 
applied to a 96-well plate and incubated over night at 4 °C. The following 
day, the plate was washed and blocked with a 5% milk solution in PBS 
with  0.1%  Tween-20.  Serums  were  diluted  from  1:50  to  1:6400  and 
incubated at room temperature for an hour. The wells were washed with 
PBS-T and then incubated with an horseradish peroxidase conjugated 
anti-monkey  secondary  (Sigma-Aldrich,  St  Louis,  MO)  for  1  hour  at 
room temperature. The wells were washed with PBS-T then developed 
with TMB. The reaction was stopped with the addition of hydrochloric 
acid and absorbance was read at 650 nm on a plate reader.
Intrathecal Injection. Farm-bred sows (Sus scrofa domestica) were obtained 
from a regional farm. Five-day-old (P5) piglets received 0.5 cc/kg ketamine 
induction anesthesia and then were maintained by mask inhalation of 5% 
isoflurane in oxygen. Body temperature, electrocardiogram, and respira-
tory rate were monitored throughout the procedure. For lumbar puncture, 
piglets were placed prone and the spine was flexed in order to widen the 
intervertebral  spaces.  The  anterior–superior  iliac  spines  were  palpated 
and a line connecting the two points was visualized. The intervertebral 
space rostral to this line is ~L5–L6. Intraoperative fluoroscopy confirmed 
rostral-caudal  and  mediolateral  trajectories.  Using  sterile  technique,  a 
25-gauge needle attached to a 1-ml syringe was inserted. Gentle negative 
pressure was applied to the syringe as the needle was passed until a clear 
flash of CSF was visualized. For cisterna puncture, the head of the piglet 
was flexed while maintaining the integrity of the airway. Fluoroscopy again 
confirmed adequate trajectory. A 25-gauge needle was passed immediately 
caudal to the occipital bone, and a flash of clear CSF confirmed entry into 
the cistern magna.
For reagent delivery, the syringe was removed while the needle was 
held  in  place.  A  second  1-cc  syringe  containing  either  viral  solution 
(5.2 × 1012 vg/kg) or PBS was secured and the solution was injected into 
the intrathecal space at a slow and constant rate. After delivery, ~0.25 ml 
of sterile PBS was flushed through the spinal needle so as to ensure full 
delivery of reagent.
We  confirmed  rostral  and  caudal  intrathecal  flow  by  injecting  a 
radioopaque  agent  (Omnipaque,  GE  Healthcare,  Waukesha,  WI)  and 
recording intrathecal spread with real-time continuous fluoroscopy.
Perfusion and tissue-processing. All subjects (primate and porcine) were 
killed between 21 and 24 days postinjection. Subjects were deeply anes-
thetized  by  intramuscular  injection  of  sodium  pentobarbital  solution 
(primates) or Telazol followed by Propofol (piglets). A midventral ster-
nal thoracotomy was performed and a cannula was inserted in the aorta 
through the left ventricle. The right atrium was opened and 0.5–1 l of PBS Molecular Therapy  vol. 19 no. 11 nov. 2011  1979
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was injected through the cannula by gravity flow, followed by perfusion 
with 1 l of 4% paraformaldehyde in phosphate buffer (pH 7.4). Organs 
were removed and post-fixed 48 hours in 4% paraformaldehyde before 
further processing for histological sectioning or stored long-term in 0.1% 
NaN3 PBS solution.
Histology  and  microscopy.  Primate and porcine spinal cord segments 
were embedded in 3% agarose before cutting into 40-μm horizontal sec-
tions using a Leica VT1200 vibrating microtome (Leica Microsystems, 
Buffalo Grove, IL). Sections were transferred in Tris-buffered saline and 
stored at 4 °C until processing.
Primate  and  porcine  brains  were  cryoprotected  by  successive 
incubation  in  10,  20,  and  30%  sucrose  solutions.  Once  sufficiently 
cryoprotected (having sunk in 30% sucrose solution), brains were frozen 
and whole-mounted on a modified Leica SM 2000R sliding microtome 
(Leica Microsystems) in OCT (Tissue-Tek, Torrance, CA) and cut into 
40-μm coronal sections.
For  immunofluorescent  determination  of  cell  types  transduced, 
floating sections were submerged in blocking solution (10% donkey serum, 
1% Triton-X100 in Tris-buffered saline) for 1 hour followed by overnight 
incubation  in  primary  antibody  solution  at  4 °C.  The  following  primary 
antibodies were used in this study: Rabbit-anti-GFP (1:500; Invitrogen), goat-
anti-ChAT (1:100; Millipore, Billerica, MA), guinea-pig-anti-GFAP (1:1,000; 
Advanced Immunochemical, Long Beach, CA) and rabbit-anti-Iba1 (1:500; 
Dako, Carpentaria, CA). Primary antibodies were detected using Fitc-, Cy3-, 
or Cy5-conjugated secondary antibodies (1:1,000; Jackson ImmunoResearch, 
West Grove, PA) and mounted in PVA-DABCO medium.
For  immunohistochemical  staining,  sections  were  incubated  at 
room temperature in 0.5% H2O2/10% MeOH solution and subsequently 
blocked and stained as above with rabbit-anti-GFP overnight. Anti-GFP 
antibodies were detected using biotinylated donkey-anti-rabbit secondary 
antibody (1:200; Jackson ImmunoResearch) and developed using Vector 
NovaRed  per  the  provided  protocol  (Vector  Labs,  Burlingame,  CA). 
Sections  were  then  mounted  in  Cytoseal  60  medium  (Thermo  Fisher 
Scientific, Kalamazoo, MI).
Non-neural tissues were cut to ~1 cm3 blocks and cryoprotected by 
overnight incubation in 30% sucrose solution. They were then embedded 
in gum tragacanth and flash-frozen in liquid nitrogen-cooled isopentane. 
Samples were cut by cryostat into 10–12 μm sections and slides stored at 
−20 °C. GFP expression was detected by a similar immunofluorescent 
protocol  as  above  with  the  addition  of  DAPI  in  secondary  antibody 
solution (1:1,000; Invitrogen).
Fluorescent images were captured using a Zeiss 710 Meta confocal 
microscope  (Carl  Zeiss  MicroImaging,  Thornwood,  NY)  located  at 
TRINCH and processed with LSM software.
Whole  brain  sections  were  scanned  to  ×40  resolution  at  the 
Biopathology Center in the Research Informatics Core at the Research 
Institute at Nationwide Children’s Hospital using an Aperio automated 
slide scanner (Aperio, Vista, CA) and resulting images were processed 
with ImageScope software.
In situ hybridization. As described previously,11 we generated antisense 
and sense DIG-UTP-labeled GFP riboprobes. Probe yield and incorpora-
tion of DIG-UTP was confirmed by electrophoresis and dot blot. Sections 
of spinal cord 10-μm thick were mounted and prepared by fixation with 
4%  paraformaldehyde,  washed  in  0.5×  SSC,  permeabilized  by  incuba-
tion in proteinase K (2.5 μg/ml), washed in 0.5 × SSC and dehydrated in 
series of alcohol washes. Prehybridization was performed at 42 °C using 
RiboHybe buffer (Ventana, Tucson, AZ) for 1 hour followed by hybridiza-
tion overnight at 55 °C with the respective riboprobes on AAV9-injected 
and  PBS-control-injected  cord  sections.  Stringency  washes  were  per-
formed and immunological detection using anti-Digoxigenin AP antibody 
(1:500; Roche, Tucson, AZ) and development with NBT/BCIP (Thermo 
Fisher Scientific) and Nuclear Fast Red (Vector Labs).
suPPleMentArY MAterIAl
Figure S1.  GFP expression with the dorsal horn of spinal cord.
Figure S2.  GFP expression in a 3-year-old monkey spinal cord.
Figure S3.  GFP immunohistochemistry from a 3-year-old monkey.
Figure S4.  GFP  immunofluorescence  from  AAV9-injected  monkey 
brain.
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